Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
CRL > SEC Filings for CRL > Form 8-K on 4-Dec-2013All Recent SEC Filings




Change in Directors or Principal Officers

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 3, 2013, the Board of Directors of Charles River Laboratories International, Inc. (the "Registrant") increased the size of the Board from eight to nine. Following the increase in the size of the Board, the Board filled the vacancy and appointed Craig B. Thompson, M.D., to the Board, effective immediately.

Dr. Thompson is expected to be appointed to a new Science and Technology Committee, which is in the process of being established. He is also expected to be appointed to the Registrant's existing Corporate Governance and Nominating Committee. There are no arrangements or understandings between Dr. Thompson and any other person pursuant to which he was selected as a director, and there are no transactions in which either Dr. Thompson has an interest requiring disclosure under Item 404(a) of Regulation S-K.

Dr. Thompson will participate in the non-employee director compensation arrangements generally applicable to all of the Registrant's non-employee directors. Under the terms of those arrangements as currently in effect, new directors will receive, among other things, stock options and restricted stock having a target value of approximately $275,000 on the first day of the month following their initial election or appointment to the Board (in the same proportions as issued to management during that same fiscal year), utilizing Black Scholes pricing models.

Dr. Thompson is President and Chief Executive Officer, Memorial Sloan-Kettering Cancer Center. Prior to joining Memorial Sloan-Kettering Cancer Center in 2010, Dr. Thompson held various roles at the University of Pennsylvania. He currently serves as a member of the Medical Advisory Board of the Howard Hughes Medical Institute; on the Board of Directors of Merck & Co., Inc.; as a member of the Lasker Prize Jury; and as Associate Editor of the journals Cell, Immunity, and Cancer Cell. Dr. Thompson holds a number of patents related to immunotherapy and apoptosis, and is a founder of three biotechnology companies. He is an elected member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences, the American Society for Clinical Investigation, and the American Association of Physicians.

Top of the Form

  Add CRL to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for CRL - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.